Breast Cancer DNA Methylation Profiles Are Associated with Tumor Size and Alcohol and Folate Intake

Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, United States of America.
PLoS Genetics (Impact Factor: 8.17). 07/2010; 6(7):e1001043. DOI: 10.1371/journal.pgen.1001043
Source: PubMed

ABSTRACT Although tumor size and lymph node involvement are the current cornerstones of breast cancer prognosis, they have not been extensively explored in relation to tumor methylation attributes in conjunction with other tumor and patient dietary and hormonal characteristics. Using primary breast tumors from 162 (AJCC stage I-IV) women from the Kaiser Division of Research Pathways Study and the Illumina GoldenGate methylation bead-array platform, we measured 1,413 autosomal CpG loci associated with 773 cancer-related genes and validated select CpG loci with Sequenom EpiTYPER. Tumor grade, size, estrogen and progesterone receptor status, and triple negative status were significantly (Q-values <0.05) associated with altered methylation of 209, 74, 183, 69, and 130 loci, respectively. Unsupervised clustering, using a recursively partitioned mixture model (RPMM), of all autosomal CpG loci revealed eight distinct methylation classes. Methylation class membership was significantly associated with patient race (P<0.02) and tumor size (P<0.001) in univariate tests. Using multinomial logistic regression to adjust for potential confounders, patient age and tumor size, as well as known disease risk factors of alcohol intake and total dietary folate, were all significantly (P<0.0001) associated with methylation class membership. Breast cancer prognostic characteristics and risk-related exposures appear to be associated with gene-specific tumor methylation, as well as overall methylation patterns.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review considers the emerging relationships between environmental factors and epigenetic alterations and the application of genome-wide assessments to better define these relationships. First we will briefly cover epigenetic programming in development, one-carbon metabolism, and exposures that may disrupt normal developmental programming of epigenetic states. In addition, because a large portion of epigenetic research has focused on cancer, we discuss exposures associated with carcinogenesis including asbestos, alcohol, radiation, arsenic, and air pollution. Research on other exposures that may affect epigenetic states such as endocrine disruptors is also described, and we also review the evidence for epigenetic alterations associated with aging that may reflect cumulative effects of exposures. From this evidence, we posit potential mechanisms by which exposures modify epigenetic states, noting that understanding the true effect of environmental exposures on the human epigenome will require additional research with appropriate epidemiologic studies and application of novel technologies. With a more comprehensive understanding of the affects of exposures on the epigenome, including consideration of genetic background, the prediction of the toxic potential of new compounds may be more readily achieved, and may lead to the development of more personalized disease prevention and treatment strategies.
    Frontiers in Genetics 11/2011; 2:84. DOI:10.3389/fgene.2011.00084
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study of normal mammalian cell growth and the defects that contribute to disease pathogenesis links metabolism to cell growth. Here, we visit several aspects of growth-promoting metabolism, emphasizing recent advances in our understanding of how alterations in glucose metabolism affect cytosolic and mitochondrial redox potential and ATP generation. These alterations drive cell proliferation not only through supporting biosynthesis, energy metabolism, and maintaining redox potential but also through initiating signaling mechanisms that are still poorly characterized. The evolutionary basis of these additional layers of growth control is also discussed.
    Cell metabolism 10/2011; 14(4):443-51. DOI:10.1016/j.cmet.2011.07.014 · 16.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Glutation S-transferase P1 (GSTP1) gene methylation in promoter CpG islands has been described as a specific biomarker for many types of cancer including breast cancer as a tumor suppressor gene. At the present study we found that the GSTP1 gene promoter to be methylated in breast cancer tissues. For studying the difference of sequence in hypermethylated GSTP1 promoter in cancer tissues and non methylated status in normal tissues, we analyzed the cytosine methylation status as epigenetic changes in 50 tumors from patients with breast cancer and 50 normal breast tissues that were obtained from the adjacent regions of the breast tumors of the same patients. In order to study the promoter methylation status for GSTP1 gene in breast cancer, 40 CpG sites [nucleotide(nt) 197 4] were screened. The GSTP1 methylation was detected in 41.3% of the breast tumors which was associated with higher tumor grade (p=0.467) and tumor stage (p = 0.048).

Preview (2 Sources)

1 Download
Available from